Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.
about
Treprostinil for the treatment of pulmonary arterial hypertensionRecent trends in pulmonary arterial hypertensionWithdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH).A systematic review of transition studies of pulmonary arterial hypertension specific medicationsSubcutaneous treprostinil is well tolerated with infrequent site changes and analgesicsSaudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension.Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension.Current and emerging therapy for primary pulmonary hypertension.Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertensionProstanoid therapies in the management of pulmonary arterial hypertension.Treprostinil for pulmonary hypertension.Transition from intravenous epoprostenol to oral or subcutaneous therapy in pulmonary arterial hypertension: a retrospective case series and systematic reviewWhen cure is care: diagnosis and management of pulmonary arterial hypertension.Iloprost for idiopathic pulmonary arterial hypertension.Medical therapeutics for pulmonary arterial hypertension: from basic science and clinical trial design to evidence-based medicine.Current treatment strategies for pulmonary arterial hypertension.Subcutaneous to intravenous prostacyclin analog transition in pulmonary hypertensionPharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years.Expert opinion on available options treating pulmonary arterial hypertension.Therapeutic advances in pulmonary arterial hypertension.Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension.Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension.The Rapid Initiation, Titration, and Transition from Intravenous to Oral Treprostinil in a Patient with Severe Pulmonary Arterial Hypertension.Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension.Treprostinil for pulmonary hypertension.Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension.Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
P2860
Q28281899-132B5F5D-65F6-4FD0-B78B-5EFD14BBD727Q30475192-6CAAEABA-4141-4B6C-9515-989C2EE23ADBQ33788506-0F91BEC6-2253-4DDE-AD15-5CFC94F100CCQ33788548-1E150CEB-8111-4644-9C09-E34A1F24BBE6Q33806168-B95AAA70-E4C2-47C5-9BC3-667BE65B59FFQ33965898-452159A4-98CB-44AC-A96F-C12A5231D7EBQ34508259-85CF5731-5D4B-4447-B9EB-D452BE41B29AQ34796981-A4EF3B7B-EA32-426E-8255-04BA347B9EA4Q35234795-03D282C4-F435-4132-A7A7-B660340659F6Q35284318-4439E9BE-6A97-45F3-890A-FCD66DECDA0DQ35777345-1F9D96FD-4715-4CD3-B214-CD658CC55E82Q35895629-E47E40FC-FD34-42BC-852D-56BA6BDE9A1DQ36062149-8E1CAE89-E63B-408B-BE02-1C35F4A46BC1Q36107191-025D7069-4407-490D-93B4-20EC044815CAQ36107232-878DB4AE-91D7-40B1-9932-EDEABD6CB133Q36237720-9749FA74-6C47-458A-A444-D4BECC0E6797Q36325779-03354E37-B631-4CFD-883E-C93063809D2FQ36408727-D0B01E65-8944-42A4-8FEC-B2DC076D9F56Q36967262-D3285D98-0F69-4ADE-8681-D4F75BE7D859Q37362631-ECCB39EF-D21B-40E1-A88F-EFC463F919F1Q37944298-5FDF89D7-EB79-40B6-B135-889401FFA2F4Q38384056-85822237-06E4-47B2-A66A-31F0CDAF8DB3Q41552385-7529BA70-18E8-4040-B823-481BCE800E89Q41926707-35CBFE24-512C-42D9-B45B-FD51DA9EB7ECQ42390990-80E71AFA-758F-4D29-B7E8-8B5FBE0DB76DQ45310654-B43CDE0B-39A6-4C87-9313-09D3887E4C0EQ55193715-6F2EABA0-FD5F-4AD9-875E-CAEA0EA4A81D
P2860
Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Transitioning from i.v. epopro ...... lmonary arterial hypertension.
@en
Transitioning from i.v. epopro ...... lmonary arterial hypertension.
@nl
type
label
Transitioning from i.v. epopro ...... lmonary arterial hypertension.
@en
Transitioning from i.v. epopro ...... lmonary arterial hypertension.
@nl
prefLabel
Transitioning from i.v. epopro ...... lmonary arterial hypertension.
@en
Transitioning from i.v. epopro ...... lmonary arterial hypertension.
@nl
P2093
P356
P1433
P1476
Transitioning from i.v. epopro ...... lmonary arterial hypertension.
@en
P2093
Diane Zwicke
Jean-Luc Vachiéry
Nicholas Hill
Robert Naeije
Robyn Barst
Shelmer Blackburn
P304
P356
10.1378/CHEST.121.5.1561
P407
P577
2002-05-01T00:00:00Z